WAT · Earnings event · Q2 2026 · archived
Waters (WAT) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $3.05 vs estimate $3.01 (+1.4%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $3.01 | $3.05 | +1.4% |
| Revenue | — | — | — |
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated WAT Hold at 6.1/10. After the Q2 2026 report, the verdict moved to Buy (Wait) at 6.4/10.
Healthcare context
WAT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $40.47B
- P/E (fwd)
- 24.9
- P/E (ttm)
- 104.1
- 52-week range
- $282.77–$420.26
- Off 52-week high
- 1.9%
- RSI (14)
- 79
- Volume vs avg
- 0.42×
- Engine score
- 5.9/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.